Form 8-K - Current report:
SEC Accession No. 0001193125-26-292834
Filing Date
2026-07-01
Accepted
2026-07-01 17:20:55
Documents
10
Period of Report
2026-06-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ck0001540171-20260629.htm   iXBRL 8-K 48435
2 EX-10.1 ck0001540171-ex10_1.htm EX-10.1 61096
  Complete submission text file 0001193125-26-292834.txt   227170

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ck0001540171-20260629.xsd EX-101.SCH 26030
13 EXTRACTED XBRL INSTANCE DOCUMENT ck0001540171-20260629_htm.xml XML 4938
Mailing Address 105 W FIRST ST. BOSTON MA 02127
Business Address 105 W FIRST ST. BOSTON MA 02127 (206) 707-0340
Avalyn Pharma Inc. (Filer) CIK: 0001540171 (see all company filings)

EIN.: 452463191 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-43251 | Film No.: 261146557
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)